Ridruejo E - Search Results

1

Ombitasvir/paritaprevir/ritonavir/dasabuvir ± ribavirin is safe and effective in HCV-infected patients in a real-life cohort from Latin America.

Mendizabal M, Haddad L, Gallardo PE, Ferrada A, Soza AA, Adrover R, Aravena E, Roblero JP, Prieto J, Vujacich C, Romero G, Muñoz A, Anders M, Hernández N, Coccozella D, Gruz F, Reggiardo MV, Ruf AE, Varón A, Cartier M, Pérez Ravier R, Ridruejo E, Peralta M, Poncino D, Vorobioff J, Aballay Soteras G, Silva MO. Mendizabal M, et al. Among authors: ridruejo e. J Med Virol. 2017 Sep;89(9):1590-1596. doi: 10.1002/jmv.24816. Epub 2017 Jun 6. J Med Virol. 2017. PMID: 28370222

2

Efficacy, tolerability and safety in the treatment of chronic hepatitis C with combination of PEG-Interferon - Ribavirin in daily practice.

Ridruejo E, Adrover R, Cocozzella D, Fernández N, Reggiardo MV. Ridruejo E, et al. Ann Hepatol. 2010 Jan-Mar;9(1):46-51. Ann Hepatol. 2010. PMID: 20308722 Free article.

3

Etiology of hepatocellular carcinoma in Latin America: a prospective, multicenter, international study.

Fassio E, Díaz S, Santa C, Reig ME, Martínez Artola Y, Alves de Mattos A, Míguez C, Galizzi J, Zapata R, Ridruejo E, de Souza FC, Hernández N, Pinchuk L; Multicenter Group for Study of Hepatocarcinoma in Latin America; Asociación Latinoamericana para el Estudio del Hígado (ALEH). Fassio E, et al. Among authors: ridruejo e. Ann Hepatol. 2010 Jan-Mar;9(1):63-9. Ann Hepatol. 2010. PMID: 20332549 Free article.

4

Effectiveness of hepatitis C treatment with pegylated interferon and ribavirin in urban minority patients.

Ridruejo E, Adrover R, Cocozzella D, Reggiardo MV, Fernández N. Ridruejo E, et al. Hepatology. 2010 Jun;51(6):2231; author reply 2231-2. doi: 10.1002/hep.23714. Hepatology. 2010. PMID: 20513017 No abstract available.

5

Thioctic acid-induced acute cholestatic hepatitis.

Ridruejo E, Castiglioni T, Silva MO. Ridruejo E, et al. Ann Pharmacother. 2011 Jul;45(7-8):e43. doi: 10.1345/aph.1Q035. Epub 2011 Jun 13. Ann Pharmacother. 2011. PMID: 21672886

6

Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice.

Ridruejo E, Adrover R, Silva MO. Ridruejo E, et al. Hepatology. 2011 Sep 2;54(3):1104-5; author reply 1105. doi: 10.1002/hep.24498. Hepatology. 2011. PMID: 21721024 No abstract available.

7

Effectiveness of entecavir in chronic hepatitis B NUC-naive patients in routine clinical practice.

Ridruejo E, Adrover R, Cocozzella D, Reggiardo MV, Estepo C, Schroder T, Paz S, Mendizábal M, Fainboim H, Mandó OG, Silva MO. Ridruejo E, et al. Int J Clin Pract. 2011 Aug;65(8):866-70. doi: 10.1111/j.1742-1241.2011.02719.x. Int J Clin Pract. 2011. PMID: 21762311

8

Genetic variation in interleukin-28B predicts SVR in hepatitis C genotype 1 Argentine patients treated with PEG IFN and ribavirin.

Ridruejo E, Solano A, Marciano S, Galdame O, Adrover R, Cocozzella D, Delettieres D, Martínez A, Gadano A, Mandó OG, Silva MO. Ridruejo E, et al. Ann Hepatol. 2011 Oct-Dec;10(4):452-7. Ann Hepatol. 2011. PMID: 21911885 Free article.

9

Entecavir in the treatment of chronic hepatitis B in kidney transplantation.

Ridruejo E, Adrover R, Mandó OG, Silva MO. Ridruejo E, et al. J Hepatol. 2012 Apr;56(4):997-8; author reply 999. doi: 10.1016/j.jhep.2011.09.019. Epub 2011 Nov 7. J Hepatol. 2012. PMID: 22075262 Free article. No abstract available.

10

Safety of long-term nucleos(t)ide treatment in chronic hepatitis B.

Ridruejo E, Silva MO. Ridruejo E, et al. Expert Opin Drug Saf. 2012 May;11(3):357-60. doi: 10.1517/14740338.2012.672972. Epub 2012 Mar 15. Expert Opin Drug Saf. 2012. PMID: 22417072

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

134 results

Search Page